Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study
Authors:
Open Access
- 16 September 2023
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (1) , 340-354
Abstract
Introduction: EASIER is a multicenter, observational, cross-sectional study investigating the consumption of healthcare resources, including healthcare professional (HCP) active working time, the costs associated with the current natalizumab intravenous (IV) administration, and the potential impact of the adoption of subcutaneous (SC) route. Methods: The EASIER study has three parts: (1) time and motion study to measure healthcare resources and working time needed for natalizumab IV administration using a digital data collection tool operated directly by HCPs; (2) HCP structured questionnaire-based estimation of the potential impact of natalizumab SC vs. IV administration; and (3) patient survey on the burden of natalizumab administration. Results: Nine Italian multiple sclerosis (MS) centers measured 404 IV natalizumab administration procedures and administered 26 HCP questionnaires and 297 patient questionnaires. Patients had a mean of 52 (range 1–176) previous IV administrations and spent a mean (median, IQR) of 152 (130, 94–184) minutes in the center per each IV procedure, with IV infusion covering 50% of the total. Including patient travel time, an average of 5 h was dedicated to each IV administration. Active working time by HCP amounted to 29 min per IV administration procedure, 70% of which by nursing staff. With adoption of the SC route, HCPs estimated a 50% reduction in patient procedure time and 55% lower HCP active working time. This translated into a 63% cost reduction for the MS center per natalizumab administration procedure. Conclusions: SC natalizumab administration will consistently reduce consumption of patient and HCP times per procedure and associated costs.Keywords
Funding Information
- Biogen Italia
This publication has 34 references indexed in Scilit:
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyThe Lancet Oncology, 2013
- Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life SettingPLOS ONE, 2013
- Subcutaneous Drug DeliveryJournal of Infusion Nursing, 2012
- Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosisMultiple Sclerosis Journal, 2011
- The economic cost of brain disorders in EuropeEuropean Journal of Neurology, 2011
- Effect of Treatment with Natalizumab on Ability to Work in People with Multiple SclerosisBioDrugs, 2011
- Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer AcetateEuropean Neurology, 2011
- Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeksMultiple Sclerosis Journal, 2010
- Health‐related quality of life in multiple sclerosis: effects of natalizumabAnnals of Neurology, 2007
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006